Relmada Therapeutics Inc ( (RLMD) ) has released its Q2 earnings. Here is a breakdown of the information Relmada Therapeutics Inc presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, with lead candidates NDV-01 and sepranolone advancing through mid-stage clinical development. In its latest earnings report, Relmada announced promising results from the 6-month follow-up of its Phase 2 study of NDV-01 for non-muscle invasive bladder cancer, showing a 91% overall response rate and good safety profile. The company also reported a significant reduction in its net loss for the second quarter of 2025, down to $9.9 million from $17.8 million in the same period last year, attributed to decreased research and development expenses. Relmada is actively preparing for the next phases of its clinical trials, with plans to initiate a Phase 3 study for NDV-01 and a Phase 2 study for sepranolone in Prader-Willi syndrome in the first half of 2026. Looking ahead, Relmada remains focused on advancing its pipeline and optimizing its financial performance, with management expressing confidence in the potential of its lead candidates to address significant unmet medical needs.